Coralan Contraindications

Hypersensitivity to ivabradine or to any excipients of Coralan; resting heart rate of <60 bpm prior to treatment; cardiogenic shock; acute myocardial infarction; severe hypotension (<90/50 mm Hg); severe hepatic insufficiency; sick sinus syndrome; sino-atrial block; heart failure patients with NYHA functional classification III-IV due to lack of data; pacemaker-dependent; unstable angina; AV-block of 3rd degree.
Combination with strong cytochrome P-450 3A4 inhibitors eg, azole antifungals (ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, oral erythromycin, josamycin, telithromycin), HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone (see Interactions, Pharmacology: Pharmacokinetics under Actions).
Use in pregnancy & lactation: There are no adequate data concerning the use of ivabradine in pregnant women. Animal reproduction studies have shown embryotoxic and teratogenic effects (see Pharmacology: Toxicology under Actions). The potential risk for humans is unknown. Therefore, ivabradine is contraindicated during pregnancy.
Animal studies indicate that ivabradine is excreted in milk. Therefore, ivabradine is contraindicated in breastfeeding women.